Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
5e5 of Anti-Nectin-4 CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human Nectin-4 Protein, His Tag (Cat. No. NE4-HP2H4) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
Expression analysis of human Nectin-4 on HEK293/Human Nectin-4 Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human Nectin-4 Stable Cell Line or negative control cell using anti-human Nectin-4 antibody followed by staining with PE anti-human IgG Fc Antibody.
Mouse Anti-Nectin-4 Antibody (Mouse IgG1) captured on CM5 chip via anti-mouse antibodies surface can bind Cynomolgus Nectin-4, His Tag (Cat. No. NE4-C52H4) with an affinity constant of 824 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Enfortumab vedotin | AGS-22M6E; ASG-22M6E; DLE8519RWM; ASG-22ME; AGS-22ME; AGS-22C3; ASG-22CE; AGS-M6; AGS-22C3E | Approved | Agensys Inc, Seagen Inc | Padcev, 备思复 | United States | Carcinoma, Transitional Cell | Astellas Pharma Us Inc | 2019-12-18 | Kidney Neoplasms; Solid tumours; Carcinoma; Carcinoma, Transitional Cell; Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms, Castration-Resistant; Urethral Neoplasms; Carcinoma in Situ; Ureteral Neoplasms; Urologic Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Hepatocellular | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| SHR-A2102 | SHR-A2102 | Phase 3 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Solid tumours; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Breast Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung | Details |
| 9MW-2821 | 9MW-2821; 9-MW2821; 9-MW-2821; 9MW2821 | Phase 3 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Solid tumours; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | Details |
| Zelenectide pevedotin | BT-8009 | Phase 3 Clinical | Bicycle Tx Ltd | Solid tumours; Ovarian Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms | Details |
| BT-7480 | BT-7480 | Phase 2 Clinical | Bicycle Therapeutics | Solid tumours; Neoplasms | Details |
| SYS-6002 | SYS-6002; SYS6002; CRB-701 | Phase 2 Clinical | Jushi Biopharmaceutical Co Ltd, CSPC Pharmaceutical Group Ltd | Solid tumours | Details |
| BA-3361 | BA3361; BA-3361 | Phase 1 Clinical | Bioatla | Neoplasms | Details |
| ETx-22 | ETx-22; LY4101174 | Phase 1 Clinical | Emergence Therapeutics AG | Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Pelvic Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| XKDCT-293 | XKDCT-293; XKDCT293 | Phase 1 Clinical | Shenzhen Celconta Life Science Co Ltd | Breast Neoplasms | Details |
| IPH-4502 | IPH4502; IPH-4502 | Phase 1 Clinical | Innate Pharma SA | Solid tumours | Details |
| LY-4052031 | LY-4052031 | Phase 1 Clinical | Eli Lilly & Company Lilly France | Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Pelvic Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| SC-101 | SC-101; SC101 | Phase 1 Clinical | Tianjin Conjustar Biotechnology Co Ltd | Solid tumours | Details |
| ADRX-0706 | ADRX-0706 | Phase 1 Clinical | Adcentrx Therapeutics Inc | Solid tumours; Carcinoma; Triple Negative Breast Neoplasms; Neoplasms; Uterine Cervical Neoplasms | Details |
| SKB-410 | SKB410; SKB-410 | Phase 1 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Solid tumours | Details |
| BAT-8007 | BAT-8007 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
This web search service is supported by Google Inc.
A-Z
